Diabetic Neuropathy Market Players:
- Hoffmann-La Roche Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott Laboratories
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- GlaxoSmithKline plc
- Lupin Limited
- Glenmark Pharmaceuticals Limited
- Assertio Holdings, Inc.
- Astellas Pharma US, Inc.
- Pfizer Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of diabetic neuropathy is evaluated at USD 5.12 Billion.
The global diabetic neuropathy market size was worth around USD 4.84 Billion in 2025 and is set to register a CAGR of more than 6.4%, exceeding USD 9 Billion revenue by 2035.
North America diabetic neuropathy market will hold over 38.8% share by 2035, driven by rising diabetes prevalence and healthcare expenditure.
Key players in the market include Hoffmann-La Roche Ltd., Abbott Laboratories, Eli Lilly and Company, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Lupin Limited, Glenmark Pharmaceuticals Limited, Assertio Holdings, Inc., Astellas Pharma US, Inc., Pfizer Inc.
